Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | ME2 | P23368 | 1/20 | 0.43 |
| ▸ | ME1 | P48163 | 1/20 | 0.43 |
| ▸ | ME3 | Q16798 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22605684 | 0.87 | OPRL1 (0.47) | CACNA1GCACNA1HENPP2OPRL1OPRM1 | |
| SCHEMBL22605671 | 0.86 | HSD11B1 (0.48) | CACNA1GCACNA1HCTSSHSD11B1HRH3 | |
| SCHEMBL22605739 | 0.85 | CTSS (0.55) | CACNA1GCACNA1HCTSSCYP3A4HSD11B1 | |
| SCHEMBL22587798 | 0.82 | CACNA1G (0.44) | CACNA1GCACNA1HC5AR1CYP3A4CYP2D6 | |
| SCHEMBL30317157 | 0.78 | HSD11B1 (0.73) | OPRL1OPRM1CTSSCYP3A4HSD11B1 | |
| SCHEMBL22594434 | 0.78 | HSD11B1 (0.73) | OPRL1OPRM1CTSSCYP3A4HSD11B1 | |
| SCHEMBL22587888 | 0.78 | TNKS (0.49) | HSD11B1HRH3ME2ME1ME3 | |
| SCHEMBL22605543 | 0.77 | HSD11B1 (0.59) | OPRL1OPRM1CTSSHSD11B1HRH3 | |
| SCHEMBL22587806 | 0.76 | HRH3 (0.45) | HSD11B1HRH3ME2ME1ME3 | |
| SCHEMBL22588034 | 0.75 | HSD11B1 (0.57) | CTSSHSD11B1HRH3ME2ME1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| CN-111848598-A | Heterocyclic ring-containing compound, application thereof and composition containing heterocyclic ring-containing compound | 健艾仕生物医药有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | CACNA1G 2524/4885CACNA1H 2517/4885ENPP2 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.